Skip to main content
    D

    Design Therapeutics Inc (DSGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $10.48
    +0.75 (+7.71%)

    Market Cap: $682.77M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    68%(15/22)
    Avg Surprise
    -5.34%
    Streak
    4 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.35
    Range$-0.39 - $-0.30
    8 analysts
    EPS Revisions
    2
    0
    7d
    2
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.36+3.4%
    60d ago$-0.36+3.8%
    30d ago$-0.35+1.9%
    7d ago$-0.35+1.9%
    Current$-0.35
    Revenue Consensus
    $0
    Range$0 - $0
    8 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.32
    Range$-0.60 - $-0.20
    8 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    8 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.32---
    Sep 26EST
    		-$-0.35---
    Jun 26
    Reported Aug 3
    		$-0.32$-0.36+11.11%Beat+5.9%
    Mar 26
    Reported Apr 28
    		$-0.29$-0.33+12.12%Beat+6.5%
    Dec 25
    Reported Mar 9
    		$-0.27$-0.33+18.18%Beat-12.5%
    Sep 25
    Reported Nov 5
    		$-0.30$-0.34+11.76%Beat-30.4%
    Jun 25
    Reported Aug 7
    		$-0.34$-0.32-6.25%Miss-61.9%
    Mar 25
    Reported May 7
    		$-0.31$-0.28-10.71%Miss-55.0%
    Dec 24
    Reported Mar 10
    		$-0.24$-0.27+10.01%Beat-14.3%
    Sep 24
    Reported Nov 7
    		$-0.23$-0.24+4.17%Beat+17.9%
    Jun 24
    Reported Aug 5
    		$-0.21$-0.23+8.70%Beat+41.7%
    Mar 24
    Reported May 8
    		$-0.20$-0.26+23.08%Beat+42.9%
    Dec 23
    Reported Mar 19
    		$-0.21$-0.31+32.26%Beat+32.3%
    Sep 23
    Reported Nov 13
    		$-0.28$-0.42+33.33%Beat+12.5%
    Jun 23
    Reported Aug 14
    		$-0.36$-0.40+10.00%Beat-33.3%
    Mar 23
    Reported May 9
    		$-0.35$-0.35+0.00%Beat-45.8%
    Dec 22
    Reported Mar 14
    		$-0.31$-0.34+8.82%Beat-55.0%
    Sep 22
    Reported Nov 3
    		$-0.32$-0.29-10.34%Miss-52.4%
    Jun 22
    Reported Aug 8
    		$-0.27$-0.25-8.00%Miss-92.9%
    Mar 22
    Reported May 9
    		$-0.24$-0.22-9.09%Miss+22.6%
    Dec 21
    Reported Mar 10
    		$-0.20$-0.23+13.04%Beat-
    Sep 21
    Reported Nov 9
    		$-0.21$-0.13-61.54%Miss-
    Jun 21
    Reported Aug 9
    		$-0.14$-0.22+36.36%Beat-
    Mar 21
    Reported May 10
    		$-0.31$-0.09-244.44%Miss-

    Key Metrics

    Valuation
    P/E Ratio-8.88EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-34.10%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio18.86xQuick Ratio18.86x
    Trading Statistics
    Beta1.69Avg Volume666.33K
    52-Week High$17.2552-Week Low$5.28

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$11.25
    SMA 20$11.85
    SMA 50$13.56
    SMA 200$12.09
    EMA 10$11.03
    EMA 20$11.77
    EMA 50$12.72
    EMA 200$11.75

    MACD

    Line: -0.88Signal: -0.71Hist: -0.17

    ADX

    ADX: 33.3+DI: 14.0-DI: 33.1

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down96.0
    PSAR$11.95

    Bollinger Bands

    Upper Band$13.72
    Lower Band$9.97
    %B Position3164%(Upper)
    Band Width0.14

    RSI (14-Day)

    Neutral
    33.8

    Momentum Oscillators

    Stoch %K15.0
    Stoch %D10.6
    Williams %R-71.0
    ROC (10d)-14.4%
    Momentum-1.76
    CCI (20d)-152.0
    MFI (14d)41.2

    Volatility Measures

    ATR (14d)$0.74(7.1%)
    StdDev (20d)0.94
    Hist Vol65.1%(High)

    Volume Flow

    VWAP$10.30
    OBV781.0K
    AD Line-2.0M
    CMF (20d)-0.237

    Volume Metrics

    Avg Vol (20d)653.6K
    Vol Ratio0.8x
    VWMA (20d)$11.82

    Pivot Points

    R3$10.50
    R2$10.25
    R1$9.99
    Pivot Point$9.73
    S1$9.47
    S2$9.22
    S3$8.96

    Advanced Oscillators

    TSI-35.63
    Ultimate Osc38.3
    KST-189.35

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$588,000$0$0$0$838,000$0
    Cost of Revenue$0$0$-14,741,000$0$0$0$149,000$0$0$0$138,000$0
    Gross Profit$0$0$14.74M$0$0$0$294,000$0$0$0$-138,000$0
    Operating Expenses$22.18M$19.71M$18.17M$19.31M$21.57M$20.42M$16.69M$16.25M$15.04M$14.40M$15.12M$18.82M
    R&D$16.39M$14.38M$13.43M$14.59M$15.74M$15.38M$12.16M$11.88M$10.52M$9.80M$11.01M$13.26M
    SG&A$5.79M$5.33M$4.74M$4.72M$5.83M$5.04M$4.54M$4.37M$4.53M$4.60M$4.11M$5.57M
    Operating Income$-22,177,000$-19,706,000$-18,169,000$-19,311,000$-21,569,000$-20,418,000$-16,694,000$-16,246,000$-15,043,000$-14,400,000$-15,121,000$-18,822,000
    Interest Income$2.01M$2.07M$2.17M$2.31M$2.49M$2.70M$3.04M$3.21M$3.25M$3.29M$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-20,165,000$-17,636,000$-15,997,000$-16,997,000$-19,083,000$-17,715,000$-13,651,000$-13,039,000$-11,793,000$-11,105,000$-11,842,000$-15,789,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-20,165,000$-17,636,000$-15,997,000$-16,997,000$-19,083,000$-17,715,000$-13,651,000$-13,039,000$-11,793,000$-11,105,000$-11,842,000$-15,789,000
    EBITDA$-22,041,000$-19,696,000$-18,525,000$-19,923,000$-22,331,000$-21,319,000$-17,983,000$-17,549,000$-16,465,000$-15,988,000$-16,819,000$-17,361,000
    EBIT$-22,177,000$-19,706,000$-18,169,000$-19,311,000$-21,569,000$-20,418,000$-16,694,000$-16,246,000$-15,043,000$-14,400,000$-15,121,000$-15,789,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about DSGN

    News

    Friedreich’s Ataxia Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | AbbVie, Minoryx Therapeutics, Takeda, Reata Pharma, Design Therapeutics

    This report from DelveInsight outlines the current landscape of Friedreich's Ataxia treatment therapies, detailing over 18 companies and 20 therapies in various stages of clinical development. It highlights key emerging...

    StreetInsider•10/15/26•Neutral

    Wells Fargo Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $26

    Wells Fargo has reiterated its Buy rating for Design Therapeutics (DSGN.US), maintaining a target price of $26. This indicates the firm's continued confidence in the company's prospects.

    Moomoo•10/12/26•Bullish

    Oppenheimer's fall 2026 SMID-cap ideas include four Strong Buy stocks

    Oppenheimer Equity Research has released its Fall 2026 SMID-cap ideas, identifying four "Strong Buy" stocks based on Seeking Alpha's Quant Rating system. Semtech Corporation, Onto Innovation, Life Time Group Holdings...

    TradingView•10/7/26•Neutral

    Oppenheimer's fall 2026 SMID-cap ideas include four Strong Buy stocks

    Oppenheimer Equity Research has released its Fall 2026 SMID-cap ideas, identifying several companies with strong quantitative profiles across various sectors. The list includes four "Strong Buy" stocks based on Seeking...

    TradingView•10/6/26•Neutral

    Design Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027

    Design Therapeutics (DSGN) receives a "Hold" rating as its lead candidate, DT-216P2, targets Friedreich Ataxia (FA). While initial 4-week data from the RESTORE-FA study showed promise...

    Seeking Alpha•10/4/26•Neutral

    DSGN Valuation and Fair Value

    P/E
    -8.9x
    P/B
    3.2x
    See GNG's fair value

    DSGN Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -34.1%

    DSGN Competitors

    CompanyTicker
    MiMedx Group IncMDXG
    Inventiva SaIVA
    Gyre Therapeutics Inc.GYRE
    4D Molecular Therapeutics IncFDMT
    Annexon IncANNX
    Pharming Group NVPHAR
    Sana Biotechnology IncSANA
    OmniAb Inc.OABI

    Sector: Healthcare

    DSGN Analyst Ratings

    Consensus
    Buy
    Analysts
    7
    Strong Buy
    2
    Buy
    5
    Hold
    0
    Sell
    0
    Strong Sell
    0

    DSGN Bull Case vs Bear Case

    Bull case

    • DSGN beat EPS estimates in 75.0% of its last 8 reported quarters.
    • 100.0% of DSGN's analyst ratings are Buy or Strong Buy.

    DSGN Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    6.3%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.35
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    2 up, 1 down

    Frequently Asked Questions About DSGN

    Does DSGN pay dividends?

    Design Therapeutics Inc (DSGN) does not currently pay a regular dividend.

    What is DSGN's market cap?

    Design Therapeutics Inc (DSGN) has a market capitalization of $682.77M with a current stock price of $10.48.

    Related stocks

    Sector: Healthcare

    All stocks starting with D

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In